Dermatologic Adverse Effects of Anticancer Therapy III: Targeted and Immunotherapies

2021 ◽  
pp. 273-316
Author(s):  
Timothy Dang ◽  
Hannah Thompson ◽  
Vincent Liu ◽  
Bernice Kwong
Keyword(s):  
Adverse Effects ◽  
Anticancer Therapy

Dermatologic Adverse Effects of Anticancer Therapy II: Cytotoxic Agents

2021 ◽  
pp. 219-271
Author(s):  
Timothy Dang ◽  
Hannah Thompson ◽  
Vincent Liu ◽  
Bernice Kwong
Keyword(s):  
Adverse Effects ◽  
Anticancer Therapy ◽  
Cytotoxic Agents

Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations

2019 ◽  
Vol 26 (3) ◽  
pp. 396-426 ◽  
Author(s):  
Roman V. Kholodenko ◽  
Daniel V. Kalinovsky ◽  
Igor I. Doronin ◽  
Eugene D. Ponomarev ◽  
Irina V. Kholodenko
Keyword(s):  
Adverse Effects ◽  
Anticancer Therapy ◽  
Structural Features ◽  
Antibody Fragments ◽  
Antibody Engineering ◽  
Antitumor Action ◽  
Antigen Specificity ◽  
Advantages And Disadvantages ◽  
Anticancer Immunotherapy ◽  
Therapy Success

Monoclonal antibodies (mAbs) are an important class of therapeutic agents approved for the therapy of many types of malignancies. However, in certain cases applications of conventional mAbs have several limitations in anticancer immunotherapy. These limitations include insufficient efficacy and adverse effects. The antigen-binding fragments of antibodies have a considerable potential to overcome the disadvantages of conventional mAbs, such as poor penetration into solid tumors and Fc-mediated bystander activation of the immune system. Fragments of antibodies retain antigen specificity and part of functional properties of conventional mAbs and at the same time have much better penetration into the tumors and a greatly reduced level of adverse effects. Recent advantages in antibody engineering allowed to produce different types of antibody fragments with improved structure and properties for efficient elimination of tumor cells. These molecules opened up new perspectives for anticancer therapy. Here, we will overview the structural features of the various types of antibody fragments and their applications for anticancer therapy as separate molecules and as part of complex conjugates or structures. Mechanisms of antitumor action of antibody fragments as well as their advantages and disadvantages for clinical application will be discussed in this review.

Complementary and Integrative Medicine to Reduce Adverse Effects of Anticancer Therapy

2018 ◽  
Vol 24 (9-10) ◽  
pp. 933-941 ◽  
Author(s):  
Elio Rossi ◽  
Cristina Noberasco ◽  
Marco Picchi ◽  
Mariella Di Stefano ◽  
Antonella Rossi ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Integrative Medicine ◽  
Anticancer Therapy ◽  
Complementary And Integrative Medicine

scholarly journals Nuclear imaging of chemotherapy-induced cardiotoxicity

2021 ◽  
Vol 20 (2) ◽  
Author(s):  
A. A. Ansheles ◽  
I. V. Sergienko ◽  
Yu. A. Prus ◽  
V. B. Sergienko
Keyword(s):  
Adverse Effects ◽  
High Efficiency ◽  
Drug Withdrawal ◽  
Imaging Techniques ◽  
Nuclear Imaging ◽  
Anticancer Therapy ◽  
Left Ventricular ◽  
Great Success ◽  
Major Disadvantage ◽  
Effective Doses

The high efficiency of modern chemotherapy has made it possible to achieve great success in the treatment of cancer. Cardiovascular adverse effects are a major disadvantage of anticancer therapy, often requiring low and less effective doses or even drug withdrawal. Nuclear imaging techniques are the most sensitive in early detection of left ventricular damage and dysfunction during chemotherapy. This review presents modern data on the potential of nuclear imaging of cardiotoxicity.

scholarly journals The Enigmatic Emerging Role of the C-Maf Inducing Protein in Cancer

Diagnostics ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 666
Author(s):  
Mario Ollero ◽  
Dil Sahali
Keyword(s):  
Nephrotic Syndrome ◽  
Adverse Effects ◽  
Receptor Tyrosine Kinase ◽  
Idiopathic Nephrotic Syndrome ◽  
Anticancer Therapy ◽  
Regulatory Circuits ◽  
Growing Body ◽  
Cell Subpopulations ◽  
T Cell Subpopulations

The C-Maf-Inducing protein (CMIP) was first described as overexpressed in T cell subpopulations of idiopathic nephrotic syndrome (INS) patients. Later, it was found concomitantly upregulated in podocytes. CMIP expression has also been reported in several types of cancer, including blood malignancies and solid tumors, in many cases accompanied by nephrotic syndrome. In addition to these observations, the duality of CMIP overexpression in the kidney and INS lesions, has been extensively reported as one of the adverse effects of anticancer therapy based on anti-receptor tyrosine kinase drugs. As a consequence, a growing body of evidence points at CMIP as playing a role in cancer. This includes its reciprocal regulatory ties with NF-κB and WT1, and the more recent reports showing an involvement in regulatory circuits in cancer cells. The ensemble of the current information justifies to propose CMIP as an important piece of the puzzle of biological systems involved in cancer and other diseases and its potential as a target.

scholarly journals Nanocarriers Used in Drug Delivery to Enhance Immune System in Cancer Therapy

Pharmaceutics ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1167
Author(s):  
Giovanna C. N. B. Lôbo ◽  
Karen L. R. Paiva ◽  
Ana Luísa G. Silva ◽  
Marina M. Simões ◽  
Marina A. Radicchi ◽  
...  
Keyword(s):  
Public Health ◽  
Drug Delivery ◽  
Immune System ◽  
Cancer Therapy ◽  
Adverse Effects ◽  
Tumor Cells ◽  
Surface Area ◽  
Materials Science ◽  
Anticancer Therapy ◽  
Cancer Therapies

Cancer, a group of diseases responsible for the second largest cause of global death, is considered one of the main public health problems today. Despite the advances, there are still difficulties in the development of more efficient cancer therapies and fewer adverse effects for the patients. In this context, nanobiotechnology, a materials science on a nanometric scale specified for biology, has been developing and acquiring prominence for the synthesis of nanocarriers that provide a wide surface area in relation to volume, better drug delivery, and a maximization of therapeutic efficiency. Among these carriers, the ones that stand out are those focused on the activation of the immune system. The literature demonstrates the importance of this system for anticancer therapy, given that the best treatment for this disease also activates the immune system to recognize, track, and destroy all remaining tumor cells.

The Influence of Specimen Thickness in Quantitative Electron Energy Loss Spectroscopy

1980 ◽  
Vol 38 ◽  
pp. 112-113
Author(s):  
Nestor J. Zaluzec
Keyword(s):  
Quantitative Analysis ◽  
Adverse Effects ◽  
Energy Loss ◽  
Electron Energy ◽  
Electron Energy Loss Spectroscopy ◽  
Materials Science ◽  
Light Element ◽  
Specimen Thickness ◽  
Element Analysis ◽  
Electron Energy Loss

The application of electron energy loss spectroscopy (EELS) to light element analysis is rapidly becoming an important aspect of the microcharacterization of solids in materials science, however relatively stringent requirements exist on the specimen thickness under which one can obtain EELS data due to the adverse effects of multiple inelastic scattering.1,2 This study was initiated to determine the limitations on quantitative analysis of EELS data due to specimen thickness.

Sign in / Sign up

Export Citation Format

Share Document